These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26735174)

  • 1. The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse.
    Riehl LM; Schulte JH; Mulaw MA; Dahlhaus M; Fischer M; Schramm A; Eggert A; Debatin KM; Beltinger C
    Oncotarget; 2016 Feb; 7(6):6620-5. PubMed ID: 26735174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma.
    Riehl L; Mulaw M; Kneer K; Beer M; Beer A; Barth TF; Benes V; Schulte J; Fischer M; Debatin KM; Beltinger C
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1687. PubMed ID: 35899825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment.
    Roth SA; Knutsen E; Fiskaa T; Utnes P; Bhavsar S; Hald ØH; Løkke C; Mestdagh P; Johansen SD; Flægstad T; Einvik C
    Cancer Lett; 2016 Mar; 372(1):128-36. PubMed ID: 26708804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients.
    Nevo I; Oberthuer A; Botzer E; Sagi-Assif O; Maman S; Pasmanik-Chor M; Kariv N; Fischer M; Yron I; Witz IP
    Int J Cancer; 2010 Apr; 126(7):1570-81. PubMed ID: 19739072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression.
    Rifatbegovic F; Frech C; Abbasi MR; Taschner-Mandl S; Weiss T; Schmidt WM; Schmidt I; Ladenstein R; Ambros IM; Ambros PF
    Int J Cancer; 2018 Jan; 142(2):297-307. PubMed ID: 28921546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
    Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
    Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
    Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
    Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell next-generation sequencing of circulating tumor cells in patients with neuroblastoma.
    Kojima M; Harada T; Fukazawa T; Kurihara S; Touge R; Saeki I; Takahashi S; Hiyama E
    Cancer Sci; 2023 Apr; 114(4):1616-1624. PubMed ID: 36571449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients.
    Thwin KKM; Ishida T; Uemura S; Yamamoto N; Lin KS; Tamura A; Kozaki A; Saito A; Kishimoto K; Mori T; Hasegawa D; Kosaka Y; Nino N; Takafuji S; Iijima K; Nishimura N
    J Mol Diagn; 2020 Feb; 22(2):236-246. PubMed ID: 31837427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations.
    Pastorino F; Capasso M; Brignole C; Giglio S; Bensa V; Cantalupo S; Lasorsa VA; Tondo A; Mura R; Sementa AR; Garaventa A; Ponzoni M; Amoroso L
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational dynamics between primary and relapse neuroblastomas.
    Schramm A; Köster J; Assenov Y; Althoff K; Peifer M; Mahlow E; Odersky A; Beisser D; Ernst C; Henssen AG; Stephan H; Schröder C; Heukamp L; Engesser A; Kahlert Y; Theissen J; Hero B; Roels F; Altmüller J; Nürnberg P; Astrahantseff K; Gloeckner C; De Preter K; Plass C; Lee S; Lode HN; Henrich KO; Gartlgruber M; Speleman F; Schmezer P; Westermann F; Rahmann S; Fischer M; Eggert A; Schulte JH
    Nat Genet; 2015 Aug; 47(8):872-7. PubMed ID: 26121086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes from Plasma of Neuroblastoma Patients Contain Doublestranded DNA Reflecting the Mutational Status of Parental Tumor Cells.
    Degli Esposti C; Iadarola B; Maestri S; Beltrami C; Lavezzari D; Morini M; De Marco P; Erminio G; Garaventa A; Zara F; Delledonne M; Ognibene M; Pezzolo A
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33915956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth, progression and chromosome instability of Neuroblastoma: a new scenario of tumorigenesis?
    Tonini GP
    BMC Cancer; 2017 Jan; 17(1):20. PubMed ID: 28056863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma.
    Calabrese FM; Clima R; Pignataro P; Lasorsa VA; Hogarty MD; Castellano A; Conte M; Tonini GP; Iolascon A; Gasparre G; Capasso M
    Oncotarget; 2016 Aug; 7(31):49246-49258. PubMed ID: 27351283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma.
    Modak S; Asante-Korang A; Steinherz LJ; Grana N
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e381-3. PubMed ID: 26181424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.
    Hunter SM; Rowley SM; Clouston D; ; Li J; Lupat R; Krishnananthan N; Risbridger G; Taylor R; Bolton D; Campbell IG; Thorne H
    Urol Oncol; 2016 Mar; 34(3):120.e9-16. PubMed ID: 26585945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
    Tan SH; Sapari NS; Miao H; Hartman M; Loh M; Chng WJ; Iau P; Buhari SA; Soong R; Lee SC
    PLoS One; 2015; 10(12):e0142466. PubMed ID: 26630576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.